Point72 Hong Kong’s Crescent Biopharma CBIO Stock Holding History

Point72 Hong Kong’s Portfolio CBIO Stock Details CBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-1	Closed	–	–	2075
2021 Q1	$0	Sell	1 -4	-80%	-$1.43K	﹤0.01%	1959
2020 Q4	$2K	Buy	+5	New	+$1.75K	﹤0.01%	1643

Other funds holding CBIO

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Point72 Hong Kong's CBIO Position: Q2 2021 in Review

Point72 Hong Kong sold out of Crescent Biopharma (CBIO) in Q2 2021, closing a stake of 1 share.

Point72 Hong Kong first reported a position in CBIO in Q4 2020 and held it in 2 quarters. The position peaked at $2K in Q4 2020. 58 funds tracked by Wall St. Rank hold CBIO as of Q2 2021.

Point72 Hong Kong reported no remaining Crescent Biopharma position as of Q2 2021 after selling out during the quarter.
Point72 Hong Kong sold 1 Crescent Biopharma share in Q2 2021.
Point72 Hong Kong first reported a position in Crescent Biopharma in Q4 2020 and held it in 2 quarters.
Point72 Hong Kong's Crescent Biopharma position peaked at $2K in Q4 2020.
58 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2021.

Based on Point72 Hong Kong's 13F filing for Q2 2021, filed 16 Aug 2021.